Polymorphisms in genes involved in autoimmune disease and the risk of FVIII inhibitor development in Italian patients with haemophilia A

Haemophilia

Volumn 16, Issue 3, 2010, Pages 469-473

  Bafunno, V ^a   Santacroce, R ^a   Chetta, M ^a   D'Andrea, G ^a   Pisanelli, D ^b   Sessa, F ^a   Trotta, T ^a   Tagariello, G ^c   Peyvandi, F ^d   Margaglione, M ^a,b  

^a UNIVERSITY OF FOGGIA   (Italy)

^b CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^c Castelfranco Veneto Hospital   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

Author keywords

Antibodies; Autoimmune disease; Haemophilia; Inhibitors; Polymorphisms; Risk factors

Indexed keywords

BLOOD CLOTTING FACTOR 8 INHIBITOR; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; INTERFERON REGULATORY FACTOR 5; INTERLEUKIN 10; NON RECEPTOR PROTEIN TYROSINE PHOSPHATASE 22; TRANSCRIPTION FACTOR FOXP3; TUMOR NECROSIS FACTOR ALPHA;

ALLELE; ANTIBODY PRODUCTION; ARTICLE; AUTOIMMUNE DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DNA SEQUENCE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HAPLOTYPE; HEMOPHILIA A; HUMAN; HUMAN CELL; IMMUNOREGULATION; ITALY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM;

ANTIGENS, CD; AUTOIMMUNE DISEASES; BLOOD COAGULATION FACTOR INHIBITORS; EXONS; FACTOR VIII; FORKHEAD TRANSCRIPTION FACTORS; GENE FREQUENCY; HEMOPHILIA A; HUMANS; INTERFERON REGULATORY FACTORS; INTERLEUKIN-10; ITALY; POLYMORPHISM, GENETIC; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 22; RISK FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77953557014     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2009.02150.x     Document Type: Article

References (23)

1. The Metabolic and Molecular Bases of Inherited Disease 1995, 3241-67. Kazazian HHTuddendham EGDAntonarakis SE. eds, 7th edn, McGraw Hill, New York
2. Gill JC. Therapy of factor VIII deficiency. Seminar. Thromb Haemost 1993, 19:1-12.
3. Wight J, Paisley S. The epidemiology of inhibitors in hemophilia A: a systematic review. Haemophilia 2003, 9:418-35.
4. Oldemburg J, Schröder J, Brackmann HH, MullerReible C, Schwaab R, Tuddendham EGD. Environmental and genetic factors influencing inhibitor development. Seminar. Hematology 2004, 41(Suppl 1):82-8.
5. Hay CRM. The epidemiology of factor VIII inhibitors. Haemophilia 2006, 12(suppl 6):23-9.
6. Schwaab R, Brackmann HH, Meyer C. Haemophilia A: mutation type determines risk of inhibitor formation. J Thromb Haemost 1995, 74:1402-6.
7. Margaglione M, Castaman G, Morfini M. The Italian AICE genetics hemophilia A database: results and correlation with clinical phenotype. Haematologica 2008, 93:722-8.
8. Astermark J, Oldenburg J, Pavlova A, Berntorp E, Lefvert AK. Polymorphisms in the IL10 but not in the IL1β and IL4 genes are associated with inhibitor development in patients with hemophilia A. Blood 2006, 107:3167-72.
9. Astermark J, Oldenburg J, Carlson J. Polymorphisms in the TNFα gene and the risk of inhibitor development in patients with hemophilia A. Blood 2006, 108:3739-45.
10. Astermark J, Wang X, Oldenburg J, Berntorp E, Lefvert AK. Polymorphisms in the CTLA4 gene and inhibitor development in patients with severe hemophilia. J Thromb Haemost 2007, 5:263-5.
11. Miller SA, Dykes DD, Polesky HE. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acid Res 1988, 16:12-5.
12. Svahn J, Capasso M, Lanciotti M. The polymorphisms 318C>T in the promoter and 49A>G in exon 1 of CTLA4 and the risk of aplastic anemia in a Caucasian population. Bone Marrow Transplant 2005, 35:89-92.
13. Koch W, Kastrati A, Bottiger C, Mehilli J, von Beckerath N. IL10 and TNFα polymorphisms and the risk of coronary artery disease and myocardial infarction. Atherosclerosis 2001, 159:137-44.
14. Wilson AG, di Giovine FS, Blakemore AIF, Duff GW. Single base polymorphism in the human tumor necrosis factor α gene detectable by coI restriction of PCR product. Hum Mol Genet 1992, 1.
15. Graham RR, Kozyrev SV, Baechler EC. A common haplotype of interferon regulatory factor 5 (IRF5) regulates splicing and expression and is associated with increased risk of systemic lupus erythematosus. Nat Genet 2006, 38:550-5.
16. Pavlova A, DiazLacava A, Zeitler H. Increased frequency of the CTLA4 + 49 A/G polymorphism in patients with acquired haemophilia A compared to healthy controls. Haemophilia 2008, 14:355-60.
17. Christiakov DA, Turakulov RI. CTLA4 and its role in autoimmune thyroid disease. J Mol Endocrinol 2003, 31:21-36.
18. Ueda H, Howson JM, Esposito L. Association of the T cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 2003, 423:506-11.
19. Kyogoku C, Langefeld CD, Ortmann WA. Genetic association of the R620W polymorphism of protein tyrosine phosphatase PTPN22 with human SLE. Am J Hum Genet 2004, 75:504-7.
20. Llorente L, Zou W, Levy Y. Role of interleukin 10 in the B lymphocyte hyperactivity and autoantibody production of the human systemic lupus erythematosus. J Exp Med 1995, 181:839-44.
21. Turner D, Grant SCD, Yonan N. An investigation of polymorphism in the interleukin 10 gene promoter. Eur J Immunogenet 1997, 24:1-8.
22. Bennet CL, Christie J, Ramsdell F. The immune dysregulation, polyendocrinopathy, enteropathy, X linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet 2001, 27:20-1.
23. Huang DR, Pirskanen R, Matell G, Lefvert AK. Tumor necrosis factor alpha polymorphism and secretion in myasthenia gravis. J Neuroimmunol 1999, 94:165-71.